Filing Analysis
Pulmatrix, Inc. filed an 8-K to announce its financial results for the second fiscal quarter ended June 30, 2026, and provided a corporate update via press release.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The filing includes an announcement of financial results and a corporate update (Exhibit 99.1).
- Interim CEO and CFO Peter Ludlum signed the report.
Pulmatrix, Inc. announced its financial results for the first fiscal quarter ended March 31, 2026, and provided a corporate update. The report was signed by Peter Ludlum, who is currently serving as both the Interim CEO and Interim CFO.
🚩 Red Flags
- Management instability: The company is currently operating with an Interim CEO who is also serving as the Interim CFO, suggesting a lack of permanent executive leadership.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Press release issued on May 15, 2026.
- Peter Ludlum is serving in a dual capacity as Interim Chief Executive Officer and Interim Chief Financial Officer.
Pulmatrix, Inc. announced the closing of a private placement of its Series B Preferred Stock on April 16, 2026. The transaction was conducted under registration exemptions and disclosed via a press release on April 21, 2026.
🚩 Red Flags
- Interim leadership: Peter Ludlum is serving as both Interim CEO and Interim CFO, suggesting management instability
- Issuance of Series B Preferred Stock often involves dilutive terms or liquidation preferences that disadvantage common stockholders
📋 Key Facts
- Closed a private placement of Series B Preferred Stock on April 16, 2026
- The offering was exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D
- Peter Ludlum is currently serving as both Interim CEO and Interim CFO
- The company issued a press release regarding the closing on April 21, 2026
Pulmatrix, Inc. has entered into a definitive merger agreement with Eos SENOLYTIX, Inc. in a reverse merger transaction that will result in Eos stockholders owning approximately 94% of the combined company. The transaction involves a total change of control, a name change to Eos SENOLYTIX, Inc., and a proposed reverse stock split.
🚩 Red Flags
- Extreme dilution of existing shareholders (retaining only 6% ownership).
- Proposed reverse stock split to maintain Nasdaq compliance or facilitate the merger.
- Total change of control with Eos designating 5 out of 6 board members.
- The company is essentially serving as a shell for a private entity's public debut.
📋 Key Facts
- Merger agreement signed on March 26, 2026, with Eos SENOLYTIX, Inc.
- Post-merger ownership split is approximately 94% for Eos stockholders and 6% for Pulmatrix stockholders.
- Pulmatrix will issue Series B Convertible Preferred Stock to an Eos affiliate for $1,000,000 in gross proceeds.
- The combined company's board will consist of six members, five of whom will be designated by Eos.
- The company will seek stockholder approval for a name change and a reverse stock split.
- A lock-up agreement restricts the sale of shares by the primary Eos stockholder for 180 days post-closing.
Pulmatrix, Inc. received a termination notice from Cullgen Inc. regarding their previously announced Merger Agreement and Plan of Reorganization. The deal, which had been in progress since November 2024, was terminated without any termination fees, leaving Pulmatrix to bear its own transaction costs.
🚩 Red Flags
- Termination of a major strategic merger that had been pending for over 15 months.
- Company is currently operating under interim leadership (Interim CEO/CFO).
- Potential loss of a primary strategic path for the company's future operations or exit.
📋 Key Facts
- Termination notice received from Cullgen Inc. on February 28, 2026.
- The original Merger Agreement was dated November 13, 2024, and amended April 7, 2025.
- No termination fees are required to be paid by either party.
- Pulmatrix and Cullgen will each bear their own respective costs and expenses related to the failed merger.
- The filing was signed by Peter Ludlum, who is serving as both Interim CEO and Interim CFO.
Pulmatrix, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release. The report was signed by Peter Ludlum, who is currently serving in a dual capacity as both Interim CEO and Interim CFO.
🚩 Red Flags
- Management instability: The company is operating with an individual serving as both Interim CEO and Interim CFO, which may indicate a lack of permanent leadership or difficulty in recruiting executive talent.
📋 Key Facts
- Released financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Peter Ludlum is currently holding both the Interim Chief Executive Officer and Interim Chief Financial Officer positions.
Pulmatrix, Inc. entered into a mutual waiver agreement with Cullgen Inc. regarding restrictions imposed during the Pre-Closing Period of their existing merger and reorganization plan. The filing confirms that the original Merger Agreement remains in full force and effect except for the specific waived compliance requirement.
🚩 Red Flags
- The waiver involves compliance with restrictive covenants (Section 5.4) typically designed to protect the value of a target or acquirer during a merger period; waiving these can sometimes signal operational shifts or liquidity needs, though not explicitly stated here.
📋 Key Facts
- The Company, Cullgen Inc., and PCL Merger Sub, Inc. entered into a mutual Waiver Agreement on December 17, 2025.
- The waiver pertains specifically to Section 5.4 of the original Merger Agreement dated November 13, 2024 (as amended April 7, 2025).
- Section 5.4 imposes restrictions on parties during the 'Pre-Closing Period'.
- All other provisions of the Merger Agreement remain unchanged and in full force.
Pulmatrix, Inc. filed an 8-K to announce its financial results for the third fiscal quarter ended September 30, 2025, and provided a corporate update via press release.
📋 Key Facts
- Reporting period: Third fiscal quarter ended September 30, 2025.
- Filing date: October 16, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
Pulmatrix, Inc. filed an 8-K to announce its financial results for the second fiscal quarter ended June 30, 2025, and provided a corporate update via press release.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2025.
- Filing date: August 6, 2025.
- The filing includes an announcement of financial results and a corporate update via Exhibit 99.1.
Pulmatrix, Inc. stockholders approved several key proposals at a special meeting on June 16, 2025, including the merger with Cullgen Inc., a reverse stock split, and an increase in authorized shares. The merger remains subject to regulatory approval from the China Securities Regulatory Commission (CSRC).
🚩 Red Flags
- Reverse stock split approved (ratio 1:2 to 1:10).
- Regulatory uncertainty regarding CSRC approval required to complete the merger.
- Change of control resulting from the merger involving >20% issuance of shares.
📋 Key Facts
- Stockholders approved Proposal No. 1: Issuance of shares representing >20% of Pulmatrix outstanding and change of control due to Cullgen merger.
- Stockholders approved Proposal No. 2: A reverse stock split with a ratio between 1-for-2 and 1-for-10, to be determined by the Board.
- Stockholders approved Proposal No. 3: Increasing authorized shares from 200,000,000 to 250,000,000.
- Stockholders approved Proposals 4 & 5 regarding Cullgen Inc. stock incentive and employee purchase plans.
- Dr. Richard Batycky was elected to the board of directors (Proposal No. 6).
- CBIZ CPAs P.C. was ratified as independent auditors for FY2025, with Ernst & Young Hua Ming LLP expected if merger completes.
Pulmatrix, Inc. filed an 8-K to furnish its quarterly earnings press release for the first fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of financial results and a corporate update.
📋 Key Facts
- Report date: May 15, 2025
- Fiscal period covered: First fiscal quarter ended March 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Interim CEO and CFO Peter Ludlum signed the report
Pulmatrix, Inc. has entered into an amendment to its merger agreement with Cullgen Inc., transitioning the transaction structure from a two-step merger to a one-step merger. Under this revised structure, Cullgen will become a wholly owned subsidiary of Pulmatrix.
🚩 Red Flags
- Transaction complexity: The shift from two-step to one-step merger can sometimes signal changes in tax structuring or regulatory considerations, though often it is for administrative efficiency.
📋 Key Facts
- Amendment No. 1 to the Merger Agreement was executed on April 7, 2025.
- The transaction structure has been changed from a two-step merger to a one-step merger.
- Cullgen will now survive as a wholly owned subsidiary of Pulmatrix through a direct merger with Merger Sub I.
- The amendment includes clarifying language regarding fractional shares.
Pulmatrix, Inc. announced the resignation of its independent auditor, Marcum LLP, and the simultaneous engagement of CBIZ CPAs P.C. as its new independent registered public accounting firm.
🚩 Red Flags
- Auditor change in a micro-cap company often warrants increased scrutiny of historical financials despite management's claims of no disagreements.
- The transition involves an entity (CBIZ) that acquired Marcum's attest business, suggesting the change may be part of a larger structural shift or firm reorganization rather than a dispute.
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on April 4, 2025.
- CBIZ CPAs P.C. was engaged by the Audit Committee to serve as the new independent auditor for the fiscal year ending December 31, 2025.
- The company stated that Marcum's reports for fiscal years 2023 and 2024 did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty or accounting principles.
- No disagreements with Marcum regarding accounting principles, financial statement disclosure, or auditing scope were reported by the Company.
Pulmatrix, Inc. filed an 8-K to announce its financial results for the fourth fiscal quarter and the twelve months ended December 31, 2024.
📋 Key Facts
- Report date: March 21, 2025
- Reporting period: Fourth fiscal quarter and twelve months ended December 31, 2024
- The filing is a standard earnings release under Item 2.02.
- Interim CEO and CFO Peter Ludlum signed the report.
Pulmatrix, Inc. announced an amendment to its Restated Bylaws regarding voting standards. The change was approved by the Board of Directors and became effective on February 11, 2025.
📋 Key Facts
- Board of Directors approved Amendment No. 2 to the Restated Bylaws on February 11, 2025.
- The amendment specifically revises Article I, Section 7 regarding voting standards language.
- Amendment is effective as of the date of approval (February 11, 2025).
Pulmatrix, Inc. held its 2024 annual meeting of stockholders on December 18, 2024. The company successfully elected two directors and ratified the appointment of Marcum LLP as its independent auditor.
📋 Key Facts
- Annual Meeting held on December 18, 2024.
- Quorum reached with 1,856,171 shares present (50.82% of outstanding common stock).
- Todd Bazemore elected to the Board of Directors (Class I) until the 2027 annual meeting.
- Christopher Cabell, M.D. elected to the Board of Directors (Class I) until the 2027 annual meeting.
- Ratification of Marcum LLP as independent registered public accounting firm for fiscal year 2024.
Pulmatrix, Inc. has entered into a definitive merger agreement to acquire Cullgen Inc., effectively resulting in a reverse takeover where Cullgen stockholders will own approximately 96.4% of the combined company. The transaction involves a significant valuation disparity and requires several shareholder votes, including approval for a reverse stock split.
🚩 Red Flags
- Reverse stock split required as part of the transaction terms.
- Significant dilution for existing Pulmatrix shareholders (96.4% ownership by Cullgen).
- Transaction is subject to China Securities Regulatory Commission approval, adding regulatory complexity/risk.
📋 Key Facts
- Pulmatrix enters merger agreement with Cullgen Inc. via two merger subs.
- Cullgen stockholders will own ~96.4% of the combined company; Pulmatrix stockholders will own ~3.6%.
- Valuation assumptions: Pulmatrix at $10.5 million and Cullgen at $280.0 million.
- Pulmatrix expects to declare a cash dividend equal to net cash exceeding $2.5 million prior to closing.
- The merger requires shareholder approval for a reverse stock split (ratio TBD).
- Board of directors will be restructured; Cullgen will designate 7 of the 8 members.
Pulmatrix, Inc. filed an 8-K to announce its financial results for the third fiscal quarter ended September 30, 2024, and provided a corporate update via press release.
📋 Key Facts
- Report date: November 8, 2024
- Reporting period: Third fiscal quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- Interim CEO/CFO Peter Ludlum signed the report.
Pulmatrix, Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders for December 18, 2024, and established record and deadline dates for stockholder proposals and director nominations.
📋 Key Facts
- 2024 Annual Meeting scheduled for Wednesday, December 18, 2024.
- Record date for stockholders entitled to vote is the close of business on October 31, 2024.
- Deadline for submission of qualified stockholder proposals (Rule 14a-8) or director nominations is October 18, 2024.
- Compliance with universal proxy rules requires notice by October 18, 2024, for stockholders intending to solicit proxies for non-company nominees.
Pulmatrix, Inc. filed an 8-K to furnish its second fiscal quarter results for the period ended June 30, 2024, and provided a corporate update via press release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Second fiscal quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- Interim CEO and CFO Peter Ludlum signed the report.
Pulmatrix, Inc. announced the departure of CEO Teofilo Raad effective July 19, 2024, and the appointment of Peter Ludlum as Interim CEO and Interim CFO. The filing details a significant severance package for Mr. Raad and the engagement of an interim executive from Danforth Advisors, LLC.
🚩 Red Flags
- Sudden departure of the CEO (even if stated as non-disagreement).
- Significant cash outflow for executive severance and bonuses totaling over $1.1M.
- Heavy reliance on an interim executive from a third-party consulting firm (Danforth Advisors) to fill both CEO and CFO roles simultaneously.
📋 Key Facts
- CEO Teofilo Raad departed effective July 19, 2024; departure was not due to any disagreement regarding company operations or practices.
- Total cash severance for Mr. Raad includes $567,294 (severance), $156,310.85 (pro-rated bonus), $283,647 (separation bonus), and $170,000 (retention bonus).
- Mr. Raad's outstanding equity awards will accelerate and become fully vested as of the separation date.
- Peter Ludlum appointed Interim CEO and Interim CFO effective July 20, 2024.
- Interim CEO services provided via Danforth Advisors, LLC at a rate of $700 per hour.
- Ludlum Retention Agreement includes two bonuses totaling $50,000 contingent on service through the Q4 2024 annual meeting.
Pulmatrix, Inc. entered into a series of agreements with MannKind Corporation involving the sale of its R&D facility and a complex intellectual property cross-licensing arrangement. The deal includes the transfer of laboratory equipment and leasehold improvements to MannKind, alongside reciprocal licensing rights for inhaled delivery technologies.
🚩 Red Flags
- Asset disposition: The company is selling its primary R&D facility and equipment, which may indicate a need for liquidity or a shift toward an asset-light model.
📋 Key Facts
- Entered into a Bill of Sale and Assignment Agreement (BSA) to transfer R&D facility in Bedford, MA to MannKind.
- Transfer includes all leasehold improvements, laboratory equipment, and related personal property.
- MannKind will assume all obligations under the Company's existing lease at 36 Crosby Drive via a Lease Assignment Agreement.
- Intellectual Property Cross License Agreement (IPA) grants MannKind exclusive licenses for iSPERSE formulations of Clofazimine, insulin, and certain other APIs.
- The IPA also grants Pulmatrix exclusive rights to develop/sell the 'Cricket' single-use disposable dry powder inhaler for dihydroergotamine.
- A Master Services Agreement (MSA) establishes that MannKind will provide development services to Pulmatrix.
- Transactions are expected to close in July 2024.
Pulmatrix, Inc. issued an 8-K to announce the publication of Phase 1 clinical study results for PUR3100 in a peer-reviewed journal regarding safety and pharmacokinetics.
📋 Key Facts
- Published study: 'Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100... versus intravenous dihydroergotamine'.
- Study Type: Phase 1 randomized, double-blind study in healthy adults.
- Publication Venue: Headache: The Journal of Head and Face Pain.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and the information is not considered 'filed' for purposes of Section 18 liability.
Pulmatrix, Inc. filed an 8-K to furnish its first fiscal quarter financial results for the period ended March 31, 2024, and a corporate update via press release.
📋 Key Facts
- Report date: May 10, 2024
- Reporting period: First fiscal quarter ended March 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information was furnished via press release dated May 10, 2024 (Exhibit 99.1)
Pulmatrix, Inc. filed an 8-K to announce its financial results for the fourth fiscal quarter and twelve months ended December 31, 2023, alongside a corporate update.
📋 Key Facts
- Reporting period: Fourth fiscal quarter and twelve months ended December 31, 2023.
- Filing date: March 28, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
Pulmatrix, Inc. announced the termination of Chief Medical Officer Dr. Margaret Wasilewski effective March 7, 2024. The company stated the departure is due to a strategic shift toward an outsourced, part-time CMO model rather than any disagreement regarding operations or policies.
🚩 Red Flags
- Elimination of a key C-suite role (CMO) in a clinical-stage biotech can sometimes signal cost-cutting measures due to liquidity constraints.
- Transitioning from an internal CMO to an outsourced model may impact continuity of clinical oversight.
📋 Key Facts
- Termination date: March 7, 2024
- Departing Officer: Dr. Margaret Wasilewski, Chief Medical Officer (CMO)
- Reason for departure: Elimination of the full-time position to transition to an outsourced, part-time model
- The company explicitly stated there was no disagreement regarding operations, policies, or practices.
- Severance and unpaid bonuses will be paid per the employment letter dated January 27, 2022.
Pulmatrix, Inc. filed an 8-K to furnish a corporate presentation intended for use at industry conferences and with the investment community. This is a standard regulatory filing under Item 7.01 (Regulation FD Disclosure) used to disseminate non-material information.
📋 Key Facts
- The company intends to present/distribute a slide presentation (Exhibit 99.1) at various industry and other conferences.
- The corporate presentation is dated March 2024.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Pulmatrix, Inc. has entered into a Third Amendment to its Cipla Agreement that terminates the Phase 2b clinical study of its lead product, Pulmazole (PUR1900). The amendment shifts all international development and commercialization responsibilities and costs exclusively to Cipla.
🚩 Red Flags
- Termination of Phase 2b clinical study suggests a pivot or setback in the primary development path for Pulmazole.
- Significant shift in cost/responsibility: While Cipla takes on international costs, the termination of active clinical trials is a major operational change.
- CEO retention bonus structure ($170k/quarter) specifically mentions 'closing date of a potential acquisition' or 'liquidation event,' which often signals management preparing for an exit or facing liquidity pressure.
📋 Key Facts
- Effective Date: January 6, 2024.
- The Third Amendment terminates the Phase 2b clinical study of Pulmazole (PUR1900).
- Cipla will now conduct all development and commercialization in territories outside the U.S. at its own sole cost and expense.
- Company to implement a 'Development Wind Down Plan' to terminate the Phase 2b study as soon as possible, with enrollment closing by July 30, 2024.
- Cost sharing for wind-down: Company pays 60% of Direct Costs; Cipla pays 40%. Non-Direct costs are split 50/50.
- CEO Teofilo Raad granted a retention bonus of $170,000 per quarter for Q1 and Q2 2024 to ensure continuity through potential liquidity events.